AD
Therapeutic Areas
Clene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CNM-Au8 | Amyotrophic Lateral Sclerosis (ALS) | Phase 2/3 |
Leadership Team at Clene
RE
Rob Etherington
President & CEO
MM
Mark Mortenson
Chief Science Officer
MH
Michael Hotchkin
Chief Development Officer
MB
Morgan Brown
Chief Financial Officer
BG
Benjamin Greenberg
Head of Medical
JZ
Joanne Zhongyan Zhang
Director of Micro and Biology
DK
D. Kyle Pierce
Vice President, Research & Development
AR
Austin Rynders
Vice President, Clinical Operations
JM
Jerry Miraglia
General Counsel and Corporate Secretary
MA
Mary Anne McNeil
Head of Human Resources